Pfizer Inc
Pfizer Inc (PFE) is listed on NYSE and classified in Drug Manufacturers - General, part of the Healthcare sector. It is headquartered in New York, United States and has 75,000 employees. The company is worth $173.38B and trades at 40.0x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $62.58B in fiscal 2025, down 1.6% from the year before. Net income was $7.77B. The share price is within 3% of its 52-week high. It pays a dividend yielding 5.65%, and has raised its annual dividend for 15 years in a row in our records. 7 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Cliff Asness (AQR Capital Management), at $445.02M. In that quarter, 6 of them opened or added to the position and 1 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -44.9% over 5Y.
today you would have $881.11▼ -11.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 19 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $24.90 | $26.53 | $28.79 | $51.24 | $59.05 | $36.81 | $37.17 | $41.41 | $34.36 | $30.82 | $30.63 | $29.55 | $29.06 | $23.80 | $20.53 | $16.61 | $17.26 |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings growing 0.0% a year plus a 5.7% dividend yield. Growth capped at 25%.
Median P/E of 24.3 among peers in the sector.
Median P/E of 17.2 across this company’s own years on record.
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Dividend growing 5.5% a year against a 7.0% required return, from the stock’s beta.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| NVONovo Nordisk A S | $39.43 | 9.6x | 5.3x | 4.57% | 59.81% | $174.01B |
| ABTAbbott Laboratories | $102.51 | 37.4x | 3.4x | 2.46% | — | $177.38B |
| DHRDanaher Corp | $229.75 | 38.7x | 3.0x | 0.70% | 8.19% | $161.51B |
| ISRGIntuitive Surgical Inc | $443.85 |
| $16.80 |
| $21.57 |
| P/E | 17.2x | 18.3x | 18.8x | 77.8x | 9.4x | 15.3x | 22.6x | 13.2x | 22.1x | 10.3x | 27.8x | 29.1x | 21.9x | 9.6x | 12.9x | 17.0x | 17.2x | 14.8x | 14.8x | 19.4x |
| P/S | 3.3x | 2.3x | 2.4x | 2.7x | 2.8x | 4.1x | 4.9x | 5.3x | 5.9x | 4.1x | 3.7x | 4.1x | 3.8x | 3.8x | 3.3x | 2.7x | 2.1x | 3.0x | 2.5x | 3.3x |
| P/B | 2.6x | 1.6x | 1.7x | 1.8x | 3.0x | 4.3x | 3.2x | 3.4x | 3.8x | 3.0x | 3.2x | 3.1x | 2.7x | 2.6x | 2.2x | 2.0x | 1.6x | 1.6x | 2.1x | 2.4x |
| EPS | $1.36 | $1.41 | $0.37 | $5.47 | $3.85 | $1.63 | $2.82 | $1.87 | $3.34 | $1.11 | $1.05 | $1.35 | $3.03 | $1.84 | $1.20 | $0.97 | $1.17 | $1.14 | $1.11 |
| Dividend yield | 3.69% | 6.91% | 6.33% | 5.70% | 3.12% | 2.64% | 3.92% | 3.68% | 3.12% | 3.53% | 3.69% | 3.47% | 3.34% | 3.13% | 3.51% | 3.70% | 4.11% | 4.40% | 7.23% | 5.10% |
| Payout | 70.59% | 126.47% | 119.15% | 443.24% | 29.25% | 40.52% | 88.47% | 48.45% | 69.00% | 36.36% | 102.56% | 100.90% | 73.24% | 30.09% | 45.36% | 62.99% | 70.59% | 65.04% | 106.67% | 99.15% |
| Profit margin | 17.53% | 12.42% | 12.62% | 3.56% | 31.01% | 27.04% | 21.99% | 39.18% | 27.32% | 40.55% | 13.66% | 14.25% | 18.42% | 42.65% | 26.66% | 16.40% | 12.67% | 17.53% | 16.78% | 16.82% |
| ROE | 12.81% | 8.99% | 9.11% | 2.38% | 32.79% | 28.47% | 14.48% | 25.38% | 17.59% | 29.88% | 12.12% | 10.75% | 12.81% | 28.83% | 17.93% | 12.18% | 9.40% | 9.59% | 14.08% | 12.51% |
Median of the years shown; P/E years above 200x are left out.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
6 methods answered, across 3 families.
Room for errors in the reported numbers.
+63.2% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| 53.7x |
| 9.6x |
| 0.00% |
| 17.93% |
| $156.8B |
| GILDGilead Sciences Inc | $157.19 | — | 16.5x | 2.09% | -20.68% | $194.91B |
| VRTXVertex Pharmaceuticals Inc | $535.17 | 31.0x | 6.7x | 0.00% | 23.54% | $135.64B |